Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mari Iida

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Cancer Letters|April 17, 2023
Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatmentMichael J Poellmann, Jiyoon Bu, DaWon Kim, et al.
Cancers|March 28, 2025
Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck CancerKourtney L Kostecki, Regan L Harmon, Mari Iida, et al.
Cancer Biology & Therapy|July 5, 2011
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximabToni M Brand, Emily F Dunn, Mari Iida, et al.
Cancer Biology & Therapy|March 12, 2009
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximabDeric L Wheeler, Mari Iida, Tim J Kruser, et al.
Cell Death Discovery|November 2, 2017
Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cellsMahmoud Toulany, Julia Maier, Mari Iida, et al.
Molecular Cancer Therapeutics|October 22, 2017
Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule PolyphenolHannah E Pearson, Mari Iida, Rachel A Orbuch, et al.
Oncotarget|June 2, 2016
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancerMahmoud Toulany, Mari Iida, Simone Keinath, et al.
Nano Letters|June 9, 2020
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced ImmunotherapyJiyoon Bu, Ashita Nair, Mari Iida, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Cancer Letters|April 17, 2023
Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatmentMichael J Poellmann, Jiyoon Bu, DaWon Kim, et al.
Cancers|March 28, 2025
Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck CancerKourtney L Kostecki, Regan L Harmon, Mari Iida, et al.
Cancer Biology & Therapy|July 5, 2011
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximabToni M Brand, Emily F Dunn, Mari Iida, et al.
Cancer Biology & Therapy|March 12, 2009
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximabDeric L Wheeler, Mari Iida, Tim J Kruser, et al.
Cell Death Discovery|November 2, 2017
Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cellsMahmoud Toulany, Julia Maier, Mari Iida, et al.
Molecular Cancer Therapeutics|October 22, 2017
Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule PolyphenolHannah E Pearson, Mari Iida, Rachel A Orbuch, et al.
Oncotarget|June 2, 2016
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancerMahmoud Toulany, Mari Iida, Simone Keinath, et al.
Nano Letters|June 9, 2020
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced ImmunotherapyJiyoon Bu, Ashita Nair, Mari Iida, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
Pageof 6